<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00752193</url>
  </required_header>
  <id_info>
    <org_study_id>2008/438</org_study_id>
    <nct_id>NCT00752193</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of a Vaginally Administered Probiotic Lactobacilli Delivery System.</brief_title>
  <official_title>Safety and Efficacy of a Vaginally Administered Probiotic Lactobacilli Delivery System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Agentschap voor Innovatie door Wetenschap en Technologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Ghent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and the efficacy of vaginally administered&#xD;
      probiotic lactobacilli in combination with antibiotic therapy (metronidazole) in women with&#xD;
      microbiologically defined bacterial vaginosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2008</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proposed research project aims at the development of a vaginal probiotic delivery system to restore and to maintain the vaginal microflora</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">206</enrollment>
  <condition>Bacterial Vaginosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Probiotic lactobacilli</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Probiotic lactobacilli</intervention_name>
    <description>Probiotic lactobacilli in combination with antibiotic therapy</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo in combination with antibiotic therapy</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Untreated Bacterial Vaginosis (BV) (asymptomatic or symptomatic) as diagnosed during&#xD;
             the screening visit using Amsel criteria.&#xD;
&#xD;
          -  Otherwise healthy? pre-menopausal women between 18-50 years of age at date of&#xD;
             screening.&#xD;
&#xD;
          -  Regular menstrual cycles (21-35 days) or amenorrheic for at least 3 months due to use&#xD;
             of a long acting progestin or continuous use of oral contraceptives.&#xD;
&#xD;
          -  Subject is willing to insert vaginal applicators.&#xD;
&#xD;
          -  Subject is willing to be asked questions about personal medical health and sexual&#xD;
             history&#xD;
&#xD;
          -  Normal Pap smear collected at the screening visit? If a subject's Visit 0 Pap smear&#xD;
             result is any of the following, the person is ineligible for participation: ASC-US&#xD;
             (atypical squamous cells of undetermined significance), AGC (atypical glandular&#xD;
             cells), ASC-H (atypical squamous cells, cannot r/o high grade lesion), LSIL (low grade&#xD;
             squamous intraepithelial lesions), HSIL (high grade squamous intraepithelial lesions),&#xD;
             adenocarcinoma in situ, adenocarcinoma, squamous cell carcinoma in situ, squamous cell&#xD;
             carcinoma or inadequate sample&#xD;
&#xD;
          -  Agree to be sexually abstinent 48 hours prior to Visit 1 (enrollment) until 48 hours&#xD;
             after application of the study product and a second time after visit 2.&#xD;
&#xD;
          -  Agree to abstain from the use of any other intravaginal product (i.e., contraceptive&#xD;
             creams, gels, foams, sponges, lubricants, douches, etc.) throughout the trial period.&#xD;
&#xD;
          -  Agree to use an adequate method of birth control for the duration of the study to&#xD;
             avoid pregnancy. Acceptable methods include a history of tubal ligation, male partner&#xD;
             with a vasectomy, a steroidal contraceptive (oral, patch, injectable or implantable),&#xD;
             IUD (Paragard or Mirena), condoms or abstinence.&#xD;
&#xD;
          -  Subject must have access to functioning refrigerator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Urogenital infection at screening or within the 21 days prior to screening. This&#xD;
             includes urinary tract infection, Trichomonas vaginalis, Neisseria gonorrhoeae,&#xD;
             Chlamydia trachomatis or Treponema pallidum. Subjects may be re-screened at least 21&#xD;
             days after the respective antibiotic or antifungal therapies have been completed.&#xD;
&#xD;
          -  History of recurrent genital herpes.&#xD;
&#xD;
          -  Diagnosis of N. gonorrhoeae, C. trachomatis, T. pallidum or T. vaginalis on two or&#xD;
             more occasions during the six months prior to screening.&#xD;
&#xD;
          -  Pregnancy or within 2 months of last pregnancy (all subjects will have a urine&#xD;
             pregnancy test prior to enrollment).&#xD;
&#xD;
          -  Lactation.&#xD;
&#xD;
          -  Vaginal or systemic antibiotic or antifungal therapy within 21 days of the Screening&#xD;
             visit or within 4 months of Enrollment visit.&#xD;
&#xD;
          -  Investigational drug use within 4 months or 10 half-lives of the drug, whichever is&#xD;
             longer, of enrollment visit. Planned investigational drug use while participating in&#xD;
             this study.&#xD;
&#xD;
          -  Menopause.&#xD;
&#xD;
          -  IUD insertion or removal within the last 3 months.&#xD;
&#xD;
          -  Pelvic surgery within the last 3 months.&#xD;
&#xD;
          -  Cervical cryotherapy or cervical laser within the last 3 months.&#xD;
&#xD;
          -  Use of a NuvaRing® within 3 days of the screening visit or during the course of the&#xD;
             study.&#xD;
&#xD;
          -  New long-acting treatments (e.g. depot formulation including medroxyprogesterone&#xD;
             acetate (DMPA) form of hormonal birth control). Subjects may be enrolled if stable (&gt;&#xD;
             3 months) on existing therapy as determined by the Principal Investigator.&#xD;
&#xD;
          -  Diabetes or other significant disease or acute illness that in the Investigator's&#xD;
             assessment could complicate the evaluation.&#xD;
&#xD;
          -  Known HIV infection or positive HIV test at screening.&#xD;
&#xD;
          -  Immunosuppressive drug within 4 months.&#xD;
&#xD;
          -  Previous participation in a L. crispatus clinical study.&#xD;
&#xD;
          -  Colposcopic findings at the enrollment visit involving significant deep disruption of&#xD;
             the epithelium.&#xD;
&#xD;
          -  Known allergy to any component (skim milk,…) of the drug or to latex (condoms).&#xD;
&#xD;
          -  Unavailable for follow-up visits.&#xD;
&#xD;
          -  History of drug or alcohol abuse.&#xD;
&#xD;
          -  At enrollment, have any social or medical condition, or psychiatric illness that, in&#xD;
             the opinion of the Investigator, would preclude provision of informed consent, make&#xD;
             participation in the study unsafe, complicate interpretation of study outcome data, or&#xD;
             otherwise interfere with achieving the study objectives.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marleen Temmerman, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Ghent</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Ghent</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://www.uzgent.be</url>
    <description>Website of the University Hospital Ghent</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 11, 2008</study_first_submitted>
  <study_first_submitted_qc>September 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2008</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginosis, Bacterial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

